Lanean...
Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C
BACKGROUND: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to...
Gorde:
| Argitaratua izan da: | Clinicoecon Outcomes Res |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6159796/ https://ncbi.nlm.nih.gov/pubmed/30288069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S171248 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|